University of Miami

Rxmp Therapeutics, Inc.

Lawrence L Horstman

Yeon S Ahn

Wenche Jy

Rifat Pamukcu

The disclosure provides a composition comprising red cell-derived microparticles (RMPs) demonstrating acetylcholine esterase (AchE) activity of less than 350 pmol/min/10particles/uL. The disclosure further provides a method of treating excessive bleeding comprising administering the composition to a subject.

Composition comprising red cell-derived microparticles and method of treating excessive bleeding

Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can be considered as universal hemostatic agents. RMP are produced from red blood cells using a high-pressure extrusion membrane shear process and can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired.

Growing community of inventors

Plantation, FL, United States of America

Lawrence L Horstman